

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Kindly Medical Instruments Co., Ltd.*

上海康德萊醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “AGM”) of Shanghai Kindly Medical Instruments Co., Ltd.* (上海康德萊醫療器械股份有限公司) (the “Company”) will be held at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC on Monday, 16 May 2022 at 2:00 p.m. for the purpose of considering and, if thought fit, passing, with or without modifications, the following resolutions:

ORDINARY RESOLUTIONS

1. To consider and approve the adoptions of the report of the Directors for the year ended 31 December 2021.
2. To consider and approve the adoption of the report of the Supervisory Committee for the year ended 31 December 2021.
3. To consider and approve the annual report of the Company for the year 2021.
4. To consider and approve the audited financial statements of the Group for the year 2021.
5. To consider and approve the Company’s profit distribution plan for the year ended 31 December 2021.
6. To consider and approve the annual financial budget of the Group for the year 2022.
7. To consider and approve the re-election of Dr. Liang Dongke as an executive Director of the Third Session of the Board.

* *For identification purposes only*

8. To consider and approve the appointment of Mr. Lin Sen as an executive Director of the Third Session of the Board.
9. To consider and approve the re-election of Mr. Zhang Weixin as a non-executive Director of the Third Session of the Board.
10. To consider and approve the re-election of Ms. Chen Hongqin as a non-executive Director of the Third Session of the Board.
11. To consider and approve the appointment of Dr. Song Yuan as a non-executive Director of the Third Session of the Board.
12. To consider and approve the appointment of Mr. Wang Ruiqin as a non-executive Director of the Third Session of the Board.
13. To consider and approve the re-election of Mr. Jian Xigao as an independent non-executive Director of the Third Session of the Board.
14. To consider and approve the re-election of Mr. Hui Hung Kwan as an independent non-executive Director of the Third Session of the Board.
15. To consider and approve the appointment of Mr. Xu Congli as an independent non-executive Director of the Third Session of the Board.
16. To consider and approve the appointment of Ms. Ma Huifang as a Supervisor of the Third Session of the Supervisory Committee.
17. To consider and approve the appointment of Mr. Shen Xiaoru as a Supervisor of the Third Session of the Supervisory Committee.
18. To consider and approve the remuneration plan for the Directors for the year end 31 December 2022.
19. To consider and approve the remuneration plan for the Supervisors for the year end 31 December 2022.
20. To consider and approve the re-appointment of KPMG and BDO China Shu Lun Pan Certified Public Accountants LLP as international and domestic auditors of the Company for the year 2022, respectively and to authorize the Board to determine their remunerations.

SPECIAL RESOLUTION

21. To consider and approve the proposed change of company name of the Company.
22. To consider and approve the proposed amendments to the Articles of Association.

23. To consider and approve the proposed adoption of the H Share Award and Trust Scheme.
24. To consider and approve the proposed authorization to the Board and/or the Delegatee to handle matters pertaining to the H Share Award and Trust Scheme.
25. (A) To consider and approve the grant of a general mandate to the Board to allot, issue and deal with additional Domestic Shares and/or H Shares during the Relevant Period. The Board may, independently or simultaneously, allot, issue and deal with additional Domestic Shares and/or H Shares (otherwise than pursuant to the issue of shares by conversion of the surplus reserve into the share capital in accordance with the PRC Company Law and the Articles of Association) that shall not exceed 10% of the respective number of Domestic Shares and/or H Shares in issue as at the date of passing the resolution. The exercise of the general mandate shall comply with conditions below:

- (i) The Board may make or grant Share sales proposal and agreements which would or might require the exercise of such power after expiry of the Relevant Period:

For the purpose of this resolution, the “Relevant Period” means the period from the date of passing this resolution until the earliest of either:

- (a) the conclusion of the next annual general meeting of the Company following the passing of this resolution at the general meeting; or
 - (b) the expiry date of 12 months after the passing of this resolution at the general meeting; or
 - (c) the date on which the authorization set out in this resolution is revoked or amended by a special resolution in a general meeting of the Company.
- (ii) The number of Domestic Shares and/or H Shares to be allotted, issued or dealt with or conditionally or unconditionally agreed to be allotted, issued or dealt with (whether pursuant to the exercise of options or otherwise by the Board) shall not exceed 10% of the respective number of Domestic Shares and/or H Shares in issue as at the date of passing the resolutions.
 - (iii) The Board will exercise the power under such mandate in accordance with the PRC Company Law, other applicable laws and regulations of the PRC and the Listing Rules as amended from time to time and upon the necessary approval from the China Securities Regulatory Commission and other relevant authorities.

- (B) The Board be and is hereby authorized to make such amendments to the Articles of Association of the Company as it thinks fit so as to increase the registered share capital and reflect the new capital structure of the Company upon the allotment, issuance of and dealing with shares as contemplated in the above paragraph (A) of this resolution in accordance with the PRC Company Law, other applicable laws and regulations in the PRC and the Listing Rules; and
- (C) Contingent on the Board resolving to allot, issue and deal with shares of the Company pursuant to paragraph (A) of this resolution, the Board be and is hereby authorized to approve, execute and do or procure to be approved, executed and done, all such documents, deeds and things as it may consider necessary in connection with the issuance, allotment of and dealing with such shares including, without limitation, determining the size of the issue, the issue price, the use of proceeds from the issue, the target of the issue and the place and time of the issue, making all necessary applications to the relevant authorities, entering into an underwriting agreement or any other agreements, and making all necessary filings and registrations with the relevant PRC, Hong Kong and other authorities.

By order of the Board
Shanghai Kindly Medical Instruments Co., Ltd.*
上海康德萊醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC, 12 April 2022

<i>Registered office, headquarters and principal place of business in the PRC:</i>	<i>Principal place of business in Hong Kong:</i>
Block 2, No. 925 Jin Yuan Yi Road	31/F, Tower Two, Times Square
Jiading District, Shanghai, the PRC	1 Matheson Street, Causeway Bay
	Hong Kong

Notes:

- (i) Any Shareholder who wishes to appoint a proxy to attend the AGM shall refer to the Company's AGM circular dated 12 April 2022 and the annual report for the year 2021. The annual report for the year 2021 includes the report of the Directors for the year 2021, the report of the Supervisory Committee for the year 2021 and the audited financial statements of the Group for the year 2021, for the information of the Shareholders.
- (ii) A Shareholder entitled to attend and vote at the AGM or its adjournment (as the case may be) is entitled to appoint one (or, if he/she/it holds two or more issued shares of RMB1.00 each in the Company more than one) proxy to attend and vote, on a poll, in his/her/its stead in accordance with the Articles of Association. A proxy needs not be a Shareholder.

* *For identification purposes only*

- (iii) A form of proxy for use at the AGM is issued and published by the Company on 12 April 2022. Whether or not you intend to attend the AGM in person, you are urged to complete and return the form of proxy in accordance with the instructions printed on the form of proxy issued and published by the Company as soon as possible. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof (as the case may be) if you so wish. In such event, your form of proxy will be deemed to have been revoked.
- (iv) In the case of the H Shareholders, a form of proxy together with any power of attorney or other authorization documents (if any) under which it is signed or a notarized copy of that power of attorney or authorization documents must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, and in the case of the Domestic Shareholders, to the Company's registered office at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC, no less than 24 hours before the time appointed for holding the AGM or any adjournment thereof (as the case may be), in order to be valid.
- (v) In order to determine the entitlement of the Shareholders to attend and vote at the AGM, the register of members of the Company will be closed from Friday, 15 April 2022 to Monday, 16 May 2022, both days inclusive, during which period no transfer of Shares will be effected. All transfers accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for H Shareholders), or the Company's registered office at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC (for Domestic Shareholders), by no later than 4:30 p.m. on Thursday, 14 April 2022.
- (vi) In the event that the profit distribution plan for the year ended 31 December 2021 be approved at the AGM, the final dividend to be approved by the Shareholders will be paid to the H Shareholders and Domestic Shareholders whose names appear on the register of members of the Company on Sunday, 29 May 2022. The register of members of the Company will be closed from Tuesday, 24 May 2022 to Sunday, 29 May 2022, both days inclusive, during which period no transfer of Shares will be registered. All transfer forms accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for H Shareholders), or the Company's registered office at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC (for Domestic Shareholders), by no later than 4:30 p.m. on Monday, 23 May 2022.
- (vii) In the case of joint registered holders of any Shares, any one of such joint registered holders may vote at the AGM, either in person or by proxy, in respect of such Shares as if he/she/it were solely entitled thereto; but should more than one of such joint registered holders be present at the AGM, either in person or by proxy, the vote of that one of them so present, whose name stands first on the register of members in respect of such Shares shall be accepted to the exclusion of the votes of the other joint registered holder(s).
- (viii) The AGM is expected to take less than half a day. Shareholders who attend the AGM shall be responsible for their own travel and accommodation expenses.

As at the date of this notice, the Board comprises Dr. Liang Dongke and Mr. Wang Cailiang as executive Directors, Mr. Zhang Weixin, Ms. Chen Hongqin and Mr. Fang Shengshi as non-executive Directors, and Mr. Dai Kerong, Mr. Jian Xigao and Mr. Hui Hung Kwan as independent non-executive Directors.